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Abstract
Background—The utility of Mycobacterium tuberculosis direct nucleic acid amplification 
testing (MTD) for pulmonary tuberculosis disease diagnosis in the United States has not been well 
described.
Methods—We analyzed a retrospective cohort of reported patients with suspected active 
pulmonary tuberculosis in 2008–2010 from Georgia, Hawaii, Maryland, and Massachusetts to 
assess MTD use, effectiveness, health-system benefits, and cost-effectiveness.
Results—Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were 
M. tuberculosis-culture-positive. Eighty percent (680/848) of patients having acid-fast-bacilli-
smear-positive specimens had MTD performed; MTD positive-predictive value (PPV) was 98% 
and negative-predictive value (NPV) was 94%. Nineteen percent (240/1292) of patients having 
smear-negative specimens had MTD; MTD PPV was 90% and NPV was 88%. Among patients 
suspected of tuberculosis but not having MTD, smear PPV for lab-confirmed tuberculosis was 
77% and NPV 78%. Compared with no MTD, MTD significantly decreased time to diagnosis in 
patients with smear-positive/MTD-positive specimens, decreased respiratory isolation for patients 
having smear-positive/MTD-negative/culture-negative specimens, decreased outpatient days of 
unnecessary tuberculosis medications, and reduced resources expended on contact investigation. 
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While MTD generally cost more than no MTD, incremental cost savings occurred in patients with 
human immunodeficiency virus (HIV) or homelessness to diagnose or to exclude tuberculosis, and 
in patients with substance abuse having smear-negative specimens to exclude tuberculosis.
Conclusions—MTD improved diagnostic accuracy and timeliness and reduced unnecessary 
respiratory isolation, treatment, and contact investigations. It was cost saving in patients with HIV, 
homelessness, or substance abuse, but not in others.
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Improvements in diagnosis of tuberculosis disease are needed. Sputum-smear microscopy 
for acid-fast-bacilli (AFB) is simple and inexpensive to perform but generally detects less 
than half of patients with culture-confirmed pulmonary Mycobacterium tuberculosis 
complex disease (culture-positivity) [1, 2] and has a poor positive predictive value (PPV) in 
persons with human immunodeficiency virus (HIV) infection [3, 4]. While culture is the 
gold standard for active tuberculosis diagnosis, it takes 2–8 weeks for results [1]. Nucleic 
acid amplification testing for M. tuberculosis can provide information within 24–48 hours. 
A meta-analysis of M. tuberculosis direct nucleic acid amplification testing (MTD, Gen-
Probe, San Diego, California) studies found sensitivity of 97% and specificity of 96% 
among smear-positive respiratory specimens, and sensitivity of 76% and specificity of 97% 
among smear-negative specimens [5].
The US Food and Drug Administration (FDA) approved the MTD in 1995 for smear-
positive specimens and an enhanced MTD in 1999 for both smear-positive and smear-
negative specimens. The Centers for Disease Control and Prevention (CDC) recommended 
in 1996 and 2000 that nucleic acid amplification testing be performed on at least one 
(preferably the first) respiratory specimen if smear-positive, and beginning in 2009 on 
smear-negative specimens from patients for whom the test result would alter tuberculosis 
case management [6].
Despite these recommendations, the request for MTD by individual providers, hospitals, and 
laboratories determines its use, which is not universal. Moreover, there are limited US data 
demonstrating the cost-effectiveness of the MTD, which might influence its use. D. W. 
Dowdy evaluated the MTD in smear-positive patients having 31.4% tuberculosis prevalence 
at a US urban hospital and found it not cost-effective for early tuberculosis exclusion in that 
setting [7].
The purpose of this study is to evaluate the use, effectiveness, health-system benefits, and 
cost-effectiveness of MTD in a retrospective cohort of patients reported to have suspected 
pulmonary tuberculosis in 2008–2010 from Georgia, Hawaii, Maryland, and Massachusetts. 
Study results will help guide future decisions about efficient MTD and provide a baseline 
for newer molecular tuberculosis disease diagnostics, such as Xpert INH/RIF (Cepheid, 
Sunnyvale, California).
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This study evaluated MTD already in use by study sites for comparison with no MTD for 
pulmonary tuberculosis diagnosis, using culture positivity as the gold standard, at 4 
independent US sites: metropolitan Atlanta, Georgia, 4 areas of Maryland, and the states of 
Hawaii and Massachusetts. Sites were evaluated on MTD use following existing CDC 
recommendations available to all US jurisdictions. We conducted retrospective reviews of 
inpatient and outpatient medical records of a 2008–2010 cohort reported to local 
tuberculosis jurisdictions with suspected pulmonary tuberculosis (see Supplementary data 
online Appendix for details). According to US standard of practice, all patients suspected of 
tuberculosis were to have ≥1 specimen from any respiratory source tested by smear and 
cultured for M. tuberculosis; any patients lacking smear/culture results were excluded. Data 
were collected from initial tuberculosis suspicion through final tuberculosis determination 
(either disease confirmation or definitive exclusion as defined by each clinician). We 
defined the date of initial tuberculosis suspicion uniformly as the earliest of respiratory 
isolation, smear positivity, tuberculosis treatment start, suspect report, or tuberculosis 
disease diagnosis as noted by the provider. We defined smear-positive as having ≥1 
positive-AFB smear and smear-negative as never having a positive-AFB smear. Similarly, 
MTD positive was defined as having ≥1 MTD-positive result and MTD-negative as never 
having a positive MTD result. CDC’s and local Institutional Review Boards waived the need 
for patient informed consent and approved the study, because it posed minimal risk to 
human subjects and involved an FDA-approved diagnostic device already in use by 
participating sites.
Person-days to event were measured from the date of initial tuberculosis suspicion to date 
of: tuberculosis-related hospitalization, inpatient respiratory isolation, tuberculosis treatment 
start, final tuberculosis determination, and contact investigation initiation. Duration of 
person-days was measured for hospitalization, respiratory isolation, intensive care, 
mechanical ventilation, outpatient treatment, and contact investigation. Person-days were 
calculated by multiplying the number of persons receiving a service by the average service 
days while the patient was suspected of having tuberculosis.
To assess associations with dichotomous outcomes, we used multivariable log-binomial 
regression (SAS version 9.2,9.3) to estimate relative risks, including in the final model all 
variables (eg, patient demographics, sites) statistically significant at the 95% confidence 
interval (CI); we report adjusted relative risks (aRR). All analyses of practices were 
stratified by smear. We used multi-variable Cox proportional hazards models to assess days 
to event and report adjusted hazard ratios (aHR) at the 95% confidence interval. A 
propensity score for use of MTD was included to adjust the model of days to final 
tuberculosis determination.
We ascribed standard costs in 2010 US dollars, updated from original sources using changes 
in the medical-care component of the US Consumer Price Index [8] or in Average Hourly 
Earnings [9], to each person-day of outcome to compute health-system costs. Unit costs per 
person per day were as follows: MTD $50 [10]; tuberculosis hospitalization $1,355 (a 
comprehensive average cost for tuberculosis-related hospitalization) [11]; physician/
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provider costs of respiratory isolation $36 [10], intensive care $114 [10], mechanical 
ventilation $65 [10]; outpatient management and medication $33 [12]; and contact 
investigation/management $2 [13]. From the health-system perspective, by smear, we 
calculated the average costs per patient evaluated with MTD versus no MTD and 
incremental cost-effectiveness (compared with no MTD) per true positive MTD and per true 
negative MTD based on culture result.
RESULTS
The cohort consisted of 2150 reported patients suspected of having pulmonary tuberculosis, 
minus 10 excluded because of missing smear or culture (N = 2140). Compared with patients 
with tuberculosis disease in 2009 reported to the US National Tuberculosis Surveillance 
System, study patients were significantly older; more likely to be non-Hispanic, of nonwhite 
race/ethnicity, or foreign-born; have HIV infection, homelessness, or injection-drug use; or 
to be employed (Table 1). One third of study patients had unknown HIV status, including 
24% of those who started tuberculosis medications.
An average of 3.6 specimens were collected and recorded per study patient. Forty percent 
(848/2140) of patients had ≥1 smear-positive specimen, and 60% (1292/2140) had all smear-
negative specimens.
Of the 2140 patients, 799 (37%) had culture-positivity (2.7 suspected patients/case). 
Foreign-born patients were 1.3 times (CI, 1.1–1.5) more likely to have culture-positivity 
than US-born patients. Patients less likely to have culture-positivity were HIV-infected (aRR 
= 0.6, CI, .5–.7), aged 25–44 (aRR = 0.9, CI, .8–1.0), or aged 45–64 (aRR = 0.8, CI, .7–.9) 
versus patients without those characteristics, controlling for site.
Fifteen percent of patients received a diagnosis of nontuberculous mycobacterial disease 
(not solely a culture of nontuberculosis mycobacterium), including 52% of patients with 
HIV infection. Patients with HIV infection (aRR = 2.3, CI, 1.7–3.2) were more likely to 
have received a diagnosis of nontuberculous mycobacterial disease than HIV-uninfected 
patients. Foreign-born patients were significantly less likely to have received a 
nontuberculous mycobacteria disease diagnosis (aRR = 0.6, CI, .4–.9), compared with other 
patients, controlling for site.
Among eventual culture-positive patients, there were fewer days from initiation of patient 
tuberculosis symptoms to clinician tuberculosis suspicion in Massachusetts (aHR = 1.4, CI, 
1.1–1.7) and Georgia (aHR = 1.5, CI, 1.1–1.9), compared with remaining sites. There were 
differences in patient composition (Table 1) and management by site.
Forty-three percent (920/2140) of the cohort was evaluated using MTD. Overall, 59% of 
hospitalized patients received MTD, versus 25% of those not hospitalized. MTD for those 
hospitalized varied by site: at Massachusetts, 35% of hospitalized received MTD versus 
18% of those not hospitalized; at Maryland, 47% versus 55%; at Hawaii, 81% versus 8%; 
and at Georgia, 98% versus 100%.
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Eighty percent (680/848) of patients having smear-positive specimens and 19% (240/1292) 
having smear-negative specimens received MTD (17% before 2009, 20% after 2009). Sixty-
one percent (418/680) of patients having ≥1 smear-positive specimen had MTD on the first 
specimen; 73% (176/240) of patients having all smear-negative specimens had MTD on the 
first specimen. Twelve percent (259/2140) of patients and 21% (73/353) with discordant 
smear/MTD results had multiple (range 2–5) MTDs documented on the same specimen 
(Table 2). Two percent (53) of patients had 3–5 MTDs on a specimen, for which results 
were sometimes reported on the same day. Among 206 (10%) patients having 2 MTDs on a 
specimen, 96% of subsequent MTDs agreed with the initial result (Table 2). Turn-around 
time from specimen collection to reported MTD result averaged 4.0 days for clinic 
specimens and 2.6 days for hospital specimens. Three percent (26/920) of patients whose 
specimens had MTD had no MTD report date recorded. MTD was conducted for 32% (7/22) 
of children < 15 years (all smear-negative); 5 were MTD- negative/culture-negative, one 
was MTD-negative/culture-positive, and one was MTD-positive/culture-positive. Figure 1 
shows MTD by population and site. From a smear-positive multivariable model, the only 
predictor of MTD was Georgia (aRR = 1.4, CI, 1.4–1.5). From a smear-negative 
multivariable model, MTD was used more often on specimens from patients who were in 
Georgia (aRR = 7.4, CI, 5.0–11.1) or in Maryland (aRR = 4.4, CI, 3.2–6.4), and less often 
on specimens from patients who were foreign-born (aRR = 0.8, CI, .6–.9) or in Hawaii (aRR 
= 0.3, CI, .2–.6) than on smear-negative specimens from other patients. Hospitalization was 
not found to be a significant predictor of MTD, controlling for site.
Fifty-four percent of patients started treatment (1161/2140), 14% after culture results were 
reported. Nearly all (355/367 smear-positive/MTD-positive, 40/40 smear-negative/MTD-
positive) patients having MTD-positive specimens were started on treatment, compared with 
23% (73/313) of smear-positive/MTD-negative and 54% (107/200) of smear-negative/
MTD-negative. The differences in days to treatment start were not statistically significant.
MTD Performance and Health-System Benefits
In patients having smear-positive specimens, MTD PPV was 98%, compared to smear PPV 
of 77% for patients who did not have MTD (ie, no MTD); in patients having smear-negative 
specimens, MTD NPV was 88% compared to smear NPV of 78% for no MTD. Among all 
subpopulations examined (HIV-infected, homeless, substance abuser, foreign born), MTD 
PPV, sensitivity, and NPV were higher than that of no MTD (Table 3). MTD was also more 
specific in all subpopulations, except those with homelessness. MTD NPV in foreign-born 
patients having smear-positive specimens was significantly lower than that in other 
subpopulations (ie, there were proportionally more false-negative MTD results in foreign-
born patients having smear-positive specimens).
For culture-negative patients having MTD-negative results compared with no MTD, there 
were significant reductions in respiratory isolation, computed tomography (CT) exams, 
bronchoscopies, and biopsies (Figure 2). There were also significantly fewer contact 
investigations initiated. Patients who had smear-negative specimens but had MTD-positive 
results and ultimately were culture-positive were significantly more likely to have received a 
bronchoscopy or a biopsy, compared to patients whose specimens had no MTD. There were 
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significantly fewer average days on outpatient medications taken while tuberculosis was 
suspected for culture-negative patients having MTD-negative specimens versus those having 
no MTD (53 fewer days for patients having smear-positive/culture-negative specimens and 
42 fewer days for smear-negative/culture-negative; Figure 3). In unadjusted analysis, MTD 
significantly decreased average time to final tuberculosis determination for all patients, 
except for those having smear-negative/MTD-positive/culture-negative specimens versus 
patients with smear-negative/no MTD/culture-negative (Figure 4). Multivariable analysis of 
time to determination of smear-positive/culture-positive found that a MTD-positive result 
speeded time to tuberculosis determination (aHR = 2.3, CI, 1.4–3.7), controlling for age 45–
64, and being at the Georgia or Maryland sites. For culture-negative patients, MTD did not 
significantly decrease time to tuberculosis exclusion in multivariable analysis.
There were some drawbacks to MTD, particularly for 4 patients having smear-negative/
MTD-positive/culture-negative results (ie, false positives) who averaged 100 days on 
outpatient tuberculosis medications and 3 of whom were placed in respiratory isolation. 
There were 18 patients having smear-positive/MTD-negative/culture-positive results (ie, 
false negatives), particularly among foreign-born patients; 19% of MTD-negative foreign-
born patients had false negative results versus 6% of all patients.
Cost-effectiveness of MTD
Hospitalization costs from initial suspicion through final tuberculosis determination 
accounted for 95% of all costs among patients suspected of pulmonary tuberculosis who 
received MTD, but outpatient management costs were greater and hospitalization costs less 
(59% of total) for patients whose specimens had no MTD. This was true for all study sites.
Among patients having smear-positive specimens, health-system costs per patient whose 
specimen received MTD averaged $17 300, versus $15 200 for those without MTD (Table 
4). For all patients, MTD cost $10 300 more per additional (incremental) smear-positive 
patient diagnosed accurately (ie, true positive) and $32 700 more per additional smear-
negative patient (ie, true negative) in health-system costs. However, there were substantial 
incremental cost savings in patients with HIV or homelessness to diagnose or to exclude 
tuberculosis, and in patients with substance abuse having smear-negative specimens to 
exclude tuberculosis. There were also incremental cost savings for smear-positive patients in 
Maryland and for smear-negative patients in Georgia (Table 4).
LIMITATIONS
We were limited to available data in medical records or lab reports. We were unable to 
assess repeat MTD resulting from inhibitor detection because of lack of documentation. 
Data were limited in Hawaii from private outpatient-care providers of patients without 
tuberculosis disease and in Massachusetts from hospitalized low-suspicion patients ruled out 
quickly. Practices in managing patients suspected of tuberculosis differed at each site, as 
they do across the US. Study findings might not be generalizable to all US settings.
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This study, conducted at 4 independent sites, comprised the largest known cohort of patients 
suspected of pulmonary tuberculosis from multiple US sites that evaluated the use, 
effectiveness, health-system benefits, and cost-effectiveness of MTD to diagnose 
tuberculosis disease. We found:
1. MTD most often for patients whose specimens were smear-positive, especially 
those in Georgia, and for Georgia/Maryland patients whose specimens were smear-
negative; MTD less often for foreign-born and Hawaii patients whose specimens 
were smear-negative,
2. significant health-system benefits in improved diagnostic accuracy, reduced time to 
tuberculosis diagnosis in smear-positive/MTD-positive, reductions in medical 
procedures and respiratory isolation for patients having smear-positive/MTD-
negative/culture-negative specimens, less time (average 1.5 months) taking 
unnecessary tuberculosis medications, and fewer resources expended on contact 
investigation for patients whose specimens were smear-positive/MTD-negative/
culture-negative compared with no MTD, and
3. incremental cost savings for patients with HIV or homelessness to either diagnose 
or exclude tuberculosis, and in patients with a history of substance abuse whose 
specimens were smear-negative to exclude tuberculosis.
The study documents detailed US practices and the diverse activities (eg, hospitalization, 
tuberculosis clinic management, and contact investigation) of multiple entities, which 
impact tuberculosis diagnostic health-system resource use. Time to initial tuberculosis 
suspicion was significantly less in Georgia and Massachusetts, which had high 
hospitalization rates. Most patients suspected of pulmonary tuberculosis were hospitalized 
prior to or on the same day that tuberculosis was initially suspected for isolation and 
evaluation, or because patients sought hospital care for other reasons. While more 
hospitalized patients received MTD, hospitalization was not an independent predictor of 
MTD, controlling for site.
We compared practices found at study sites with CDC recommendations [6]. We found a 
high percentage (80%) of ≥1 MTD in patients having ≥1 smear-positive and 20% use after 
2009 for patients having all smear-negative specimens, well over half on the first specimen 
collected. If smear and MTD results differ, additional MTD tests are recommended. Among 
353 patients having discordant smear and MTD results, only 73 (21%) had documentation of 
an additional MTD. Also recommended for smear-positive/MTD-negative specimens is 
inhibitor testing, which was rarely documented in laboratory records. MTD results appeared 
to influence providers’ decisions to start treatment but did not significantly decrease days to 
treatment start. Turn-around times (average 4.0 days for clinic specimens, 2.6 days for 
hospital specimens) were greater than the recommended 2 days. We also identified a need 
for standard lab reporting of results. Routine HIV testing is recommended for all patients 
starting tuberculosis treatment [14]. However, 33% of patients had unknown HIV status, 
including 24% of patients who started tuberculosis medications. We found that MTD was 
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highly beneficial for some groups, especially patients with HIV infection, but providers 
must test for HIV to realize these benefits.
Of the 2140 patients, a relatively high proportion (37%) had culture-positivity. Most at risk 
for tuberculosis were foreign-born patients suspected of tuberculosis, who were 3 times as 
likely as US-born patients to have culture-positivity. We found that foreign-born patients 
were significantly less likely than others suspected of tuberculosis to have received a 
diagnosis of nontuberculous mycobacterial disease. While greater MTD would benefit 
foreign-born patients suspected of tuberculosis, their significantly higher proportion of false-
negatives as a percentage of MTD-negative results (19% vs 6%) resulted in incremental 
costs rather than savings. Reasons for these false-negative MTD results, including 
assessment of specimen inhibitors, should be investigated. Compared with Greco [5], our 
study found similar MTD sensitivity in smear-positive patients and specificity in both 
smear-positive and smear-negative patients but much lower sensitivity (59% vs 76%) in 
smear-negative patients.
Hospitalization costs accounted for 95% of health-system costs among patients suspected of 
tuberculosis who received MTD and 59% of the total for no MTD. Although incremental 
cost effectiveness was higher for all patients using MTD, MTD was cost saving over no 
MTD in patients with HIV infection or homelessness to either diagnose or exclude 
tuberculosis. Targeting these populations (who often have false-positive or false-negative 
smears, are hospitalized at tuberculosis diagnosis, and are more likely to have tuberculosis-
associated deaths) for rapid tuberculosis diagnosis might reduce transmission and be life-
saving, as well as cost-saving over later diagnosis. Since a large proportion of patients 
suspected to have tuberculosis had public insurance (44%) or had no health insurance 
(29%), these cost savings to the public sector, along with added diagnostic accuracy, provide 
incentives for greater MTD in these populations. To reduce health-system costs of 
tuberculosis diagnosis, US tuberculosis providers either need to diagnose patients suspected 
of tuberculosis prior to hospitalization, which could occur with increased patient access to 
care, or to conduct critical diagnostic procedures early after hospital admission. We plan to 
assess these scenarios in a modeling study. Primary tuberculosis prevention through 
treatment of latent tuberculosis infection is also important.
CONCLUSIONS
MTD has significant health-system benefits for evaluation of patients suspected of 
pulmonary tuberculosis. MTD in both smear-positive and smear-negative specimens was 
more accurate and timely in diagnosing or ruling out tuberculosis compared with no MTD. 
MTD conserved hospital and clinic resources expended on diagnostic procedures, 
respiratory isolation, and contact investigation. MTD also reduced the burden on patients of 
unnecessary and potentially toxic tuberculosis medications. Moreover, MTD can be cost 
saving in patients with HIV, homelessness, or substance abuse. Our analysis suggests similar 
or greater health-system benefits are likely with newer molecular diagnostics that are as 
accurate, less technically complex, and less expensive to implement than MTD.
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Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) by population* 
and study site. *There was overlap among populations: Of human immunodeficiency virus 
(HIV)–infected patients, 20% were homeless, 45% were substance abusers, and 21% were 
foreign-born. Of homeless, 41% were HIV-infected, 64% were substance abusers, and 22% 
were foreign-born. Of substance abusers, 45% were HIV-infected, 31% were homeless, and 
25% were foreign-born. Of foreign born, 5% were HIV-infected, 3% were homeless, and 
6% were substance abusers. **One-third of suspected patients had unknown HIV status. 
Hawaii had <5 known HIV-infected suspected patients.
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Differences in procedures, respiratory isolation, and contact investigation initiation by 
Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) result versus no 
MTD, cases in which the smear was not predictive of tuberculosis disease. *Significant 
differences between MTD percentage and no MTD percentage at P < .05. For smear-
positive/culture-negative, n = 39 for no MTD, n = 295 for MTD-negative, n = 9 for MTD-
positive. For smear-negative/culture-positive, n = 233 for no MTD, n = 25 for MTD-
negative, n = 36 for MTD-positive. Abbreviation: MTD, Mycobacterium tuberculosis direct 
nucleic acid amplification testing.
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Differences in outpatient days on tuberculosis medications by Mycobacterium tuberculosis 
direct nucleic acid amplification testing (MTD)–negative result versus no MTD. 
*Significant differences between no MTD days and MTD-negative days at P < .05. 
Abbreviation: MTD, Mycobacterium tuberculosis direct nucleic acid amplification testing.
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Days to final tuberculosis determination by tuberculosis disease status. A, Patients with 
tuberculosis disease. Significantly fewer average days to tuberculosis disease determination 
at P < .05 for smear-positive/Mycobacterium tuberculosis direct nucleic acid amplification 
testing (MTD)–positive versus smear-positive/no MTD. B, Patients without tuberculosis 
disease. Significantly fewer average days to exclude tuberculosis at P < .05 for: smear-
positive/MTD-positive versus smear-positive/no MTD; smear-positive/MTD-negative 
versus smear-positive/no MTD; smear-negative/MTD-negative versus smear-negative/no 
MTD. Abbreviation: MTD, Mycobacterium tuberculosis direct nucleic acid amplification 
testing.
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